Brief: Brainstorm Cell Therapeutics Announces Full Year 2022 Financial Results
30/03/2023 12:28
March 30 (Reuters) - Brainstorm Cell Therapeutics Inc
BCLI.O :
* BRAINSTORM CELL THERAPEUTICS ANNOUNCES FULL YEAR 2022
FINANCIAL
RESULTS AND PROVIDES A CORPORATE UPDATE
* BRAINSTORM CELL THERAPEUTICS - NET LOSS PER SHARE FOR
TWELVE
MONTHS ENDED DECEMBER 31, 2022 WAS $0.66
* BRAINSTORM CELL - CASH, CASH EQUIVALENTS, AND SHORT-TERM
BANK
DEPOSITS WERE APPROXIMATELY $3 MILLION AS OF DEC 31, 2022
Source text for Eikon: ID:nPnc0MkKza
Further company coverage: BCLI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview